SecBot SecBot
8-K ·Filed Sep 23, 2026

NTRB

NutriBand Inc.
NEUTRAL
Impact 3/10
Horizondays Processed1mo ago SEC0001213900-26-102721
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor warrant exercise activity through September 30 deadline; full exercise would add ~$5.9M cash and ~910K shares of dilution. The company's decision not to extend or reprice suggests it is comfortable with current capital position or expects limited exercise at the $6.43 strike.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
NTRB ▼ -35.37% at T+20d
NEUTRAL call -35.37% · α vs SPY -34.95% · entry $8.99 → $5.81
Next anchor: T+60d in 7w
Latest observation: T+21 -50.52% FF3 residual α
Entry = T+0 close
Sep 23, 2026
via day close
T+1d
-11.01%
call -11.01% · α -11.56%
$8.00
settled 5w ago
T+5d
-18.13%
call -18.13% · α -17.72%
$7.36
settled 27d ago
T+20d
-35.37%
call -35.37% · α -34.95%
$5.81
settled 6d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

Nutriband filed an 8-K confirming its publicly traded warrants (NTRBW) will expire on September 30, 2026 at 5PM ET with no extension or repricing. There are 910,904 warrants outstanding at a $6.43 strike price, representing up to $5.86 million in potential proceeds if fully exercised. This is a routine administrative event that does not affect the common stock (NTRB).

Key Facts

  • Warrants expire on September 30, 2026 at 5PM ET
  • Strike price is $6.43 per warrant
  • 910,904 warrants outstanding
  • Potential proceeds to company if fully exercised: $5,856,112
  • No extension or repricing of warrants
  • Trading in warrants ceases at close of market on September 30, 2026
  • Warrants will be removed from Nasdaq listing after expiration
  • Common stock (NTRB) continues trading on Nasdaq unaffected

Financial Impact

Up to $5.86 million in potential proceeds if all 910,904 warrants are exercised at $6.43 per share before expiration

cashdilution

Risk Factors

  • If warrant holders do not exercise, the company forgoes up to $5.86 million in potential proceeds
  • Exercise of all warrants would result in approximately 910,904 new common shares, diluting existing shareholders

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-102721
Document: ea030642401ex3-1e.htm0001213900-26-102721
Document: 0001213900-26-102721-index-headers.html0001213900-26-102721
Document: 0001213900-26-102721-index.html0001213900-26-102721
Document: 0001213900-26-102721.txt0001213900-26-102721
3 reports for NTRB
Performance horizon
Filters
Rows
Reports for NTRB — sortable, filterable
TypeNow
Oct 1, 2026
25d ago
Press Release
NEUTRAL ★ 4/10
$7.28awaiting T+20—$5.97 (−17.99%)
Sep 23, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$8.99 $5.81▼ −35.37%▼ −34.95%$5.97 (−33.59%)
Mar 30, 2026
30w ago
Press Release
NEUTRAL ★ 3/10
$3.53 $3.80▲ +7.65%▼ −1.77%$5.97 (+69.12%)
Showing 3 of 3

US Market Status

Market Closed — Opens in 9h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 23, 2026